Upgrade to SI Premium - Free Trial

Amgen (AMGN) to Make Repatha Available Exclusively at Lower List Price Option

October 24, 2019 9:01 AM
Amgen (NASDAQ: AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Management Comments

Next Articles